Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 3 » Issue 2

The treatment of generalized anxiety disorder with pregabalin, an atypical anxiolytic

Authors Jeffrey R Strawn, Thomas D Geracioti Jr

Published 15 May 2007 Volume 2007:3(2) Pages 237—243

Jeffrey R Strawn1,2,3, Thomas D Geracioti Jr1,2,3

1Department of Psychiatry, University of Cincinnati, College of Medicine, Cincinnati, OH, USA; 2Research and 3Psychiatry Services, Cincinnati Veterans Affairs Medical Center Cincinnati, OH, USA

Abstract: A constellation of pharmacologic treatments for generalized anxiety disorder (GAD) have been developed over the past five decades, although each has a number of potential drawbacks in clinical practice. This review addresses one potentially new pharmacologic treatment for generalized anxiety disorder, the gamma-aminobutyric acid analogue pregabalin. We review the mechanism of action, and pharmacokinetic and pharmacodynamic properties of pregabalin as well as the results of 5 double-blind, placebo-controlled trials of pregabalin in the treatment of generalized anxiety disorder (GAD). Based entirely on data from these industry-sponsored (Pfizer), multi-site clinical trials in patients with GAD, pregabalin appears to be generally well tolerated and has rapid onset of action (approximately 1 week), comparable efficacy to benzodiazepines and lower discontinuation rates compared with other pharmacologic treatments. Thus in GAD, a disorder that is often suboptimally responsive to traditional psychotherapeutic and psychopharmacologic interventions – secondary to poor efficacy, tolerability, and/or side-effects – pregabalin may have a primary role in GAD patients, especially in those with certain psychiatric comorbidities or individuals who are on multi-drug regimens for medical comorbidities.

Keywords: GAD, pregabalin, panic attack, anxiety disorders, antidepressant, anxiolytic

Download Article [PDF] 

Readers of this article also read:

Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz

Larru B, Eby J, Lowenthal ED

Pediatric Health, Medicine and Therapeutics 2014, 5:29-42

Published Date: 29 May 2014

Spirituality in childhood cancer care

Lima NN, do Nascimento VB, de Carvalho SM, Neto ML, Moreira MM, Brasil AQ, Celestino Junior FT, de Oliveira GF, Reis AO

Neuropsychiatric Disease and Treatment 2013, 9:1539-1544

Published Date: 9 October 2013

Visuomotor competencies and primary monosymptomatic nocturnal enuresis in prepubertal aged children

Esposito M, Gallai B, Parisi L, Roccella M, Marotta R, Lavano SM, Mazzotta G, Patriciello G, Precenzano F, Carotenuto M

Neuropsychiatric Disease and Treatment 2013, 9:921-926

Published Date: 26 June 2013

Simple system using natural mineral water for high-throughput phenotyping of Arabidopsis thaliana seedlings in liquid culture

Benamar A, Pierart A, Baecker V, Avelange-Macherel MH, Rolland A, Gaudichon S, di Gioia L, Macherel D

International Journal of High Throughput Screening 2013, 4:1-15

Published Date: 28 February 2013

Predictive value of CD4 cell count nadir on long-term mortality in HIV-positive patients in Uganda

Bray S, Gedeon J, Hadi A, Kotb A, Rahman T, Sarwar E, Savelyeva A, Sévigny M, Bakanda C, Birungi J, Chan K, Yaya S, Deonandan R, Mills EJ

HIV/AIDS - Research and Palliative Care 2012, 4:135-140

Published Date: 17 August 2012

Remembering and forgetting: directed forgetting effect in obsessive-compulsive disorder

Konishi M, Shishikura K, Nakaaki S, Komatsu S, Mimura M

Neuropsychiatric Disease and Treatment 2011, 7:365-372

Published Date: 15 June 2011

Current trends in the treatment of hepatic encephalopathy

Mohamad Rasm Al Sibae, Brendan M McGuire

Therapeutics and Clinical Risk Management 2009, 5:617-626

Published Date: 31 July 2009

Experimental effect of retinoic acids on apoptosis during the development of diabetic retinopathy

Nami Nishikiori, Makoto Osanai, Hideki Chiba, Takashi Kojima, Shuichiro Inatomi, et al

Clinical Ophthalmology 2008, 2:233-235

Published Date: 7 March 2008

The therapeutic potential of escitalopram in the treatment of panic disorder

Mark H Townsend, Erich J Conrad

Neuropsychiatric Disease and Treatment 2007, 3:835-838

Published Date: 15 January 2008